Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
0 A8 Z! x4 m. z) p0 w6 B' K! y9 I3 w8 [# ]- Q( D
8 ^* ?: ~. D- [) }( l- i- I1 S0 ASub-category:* h: A0 r6 E+ c) o
Molecular Targets
' h' G5 Z- ^ D; u& B7 J/ o h; a. s4 E3 Z1 s: g$ {/ M
: k; m, X7 v9 G
Category:! B9 O# `$ W! H* ]3 d% `
Tumor Biology # E! Y* X( r9 I5 X
4 i7 h |: ^1 [" X s% H( P, y. Q( g% G$ a2 N
Meeting:; e4 W# \% J, C. f
2011 ASCO Annual Meeting
" A$ X& x" l U& r/ O7 Q1 `9 X! w, W3 \+ j* J2 w: K
6 [; P& j% I/ j Z. USession Type and Session Title:
( k4 Q/ O& @% v0 H" `' m5 v& i" P/ CPoster Discussion Session, Tumor Biology
, o$ I! z6 X* m8 S& r" p. O1 S0 m8 I$ v6 r
$ O6 l- Q* u4 R+ v2 qAbstract No:
6 `8 u% z1 r( T. M3 f" ^10517 ( n( a) r/ \2 N
+ u9 {+ M- I/ p/ u, t& s' i
" m% s' s1 w+ R6 T U6 [( k
Citation:5 \, h8 B+ t8 z# f" i7 T. w
J Clin Oncol 29: 2011 (suppl; abstr 10517)
3 j3 f6 K P' _# |0 q+ N0 a0 G
& i& U/ g p8 d; {; K/ l4 b( }3 l# [& x7 C3 r' z
Author(s):' Q5 ~! y9 ^1 W: C9 k, o
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China . d5 q; A. E- f7 a0 S
) y# d( \9 k$ [5 j0 g0 F% M6 p, H& t" v3 }
: x' c+ D" k w* t* A
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
; |( V) R' d4 o/ y5 G2 L
" U2 ~4 _4 A( S; P# W8 x+ }Abstract Disclosures2 ~0 ^7 I- H {( T1 e
6 M3 [# y. k1 H+ v! o
Abstract:* e1 e6 v' a& d9 o W7 }+ K
5 c) z2 [' z+ [: t O
3 B0 I9 _/ Y" a- Y
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- Y1 f4 {# s$ z" {, h
1 V, y2 e; o/ b6 Z2 A2 g
+ }- q2 M6 p6 p6 Q. r8 r# n0 b |
+ b7 \- d( P8 d$ c$ P. W
显身卡
